ORIGINAL RESEARCH article
Front. Stroke
Sec. Stroke in the Young
This article is part of the Research TopicChallenges in Pediatric Acute Stroke Systems of CareView all 4 articles
Challenges in acute management of cerebral sinovenous thrombosis among neonates with acute kidney injury: A retrospective cohort study
Provisionally accepted- 1Dr S N Medical College, Jodhpur, Jodhpur, India
- 2Dr Sampurnanand Medical College, Jodhpur, India
- 3University of the Philippines Manila, Manila, Philippines
- 4All India Institute of Medical Sciences Jodhpur, Jodhpur, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Cerebral sinovenous thrombosis (CSVT) in neonates with acute kidney injury (AKI) is a rare neurologic condition with potential serious consequences. Rapid diagnosis is key to good outcomes. This study aims to identify challenges in acute care and to evaluate outcomes of these patients in a resource-limited setting. Materials and Methods: This retrospective cohort study included term neonates with AKI and CSVT admitted at a tertiary center in Western India (January 2021–January 2023). Clinical profile, timing of consult with healthcare providers, diagnosis, neuroimaging, management strategies and outcomes at discharge and at 2 years were analyzed. Results: 31 neonates (19 male) with mean age 18.5 ± 6.6 days at diagnosis were included. Dehydration was the most common risk factor in 80.6%, while seizures were the most common clinical presentation (80.6% patients). Almost 84% patients had thrombosis in multiple sinuses. Venous infarcts were identified in 20 (64.5%) patients, with concomitant hemorrhage in 13 (42%). Only 10 patients received anticoagulation therapy. Median time from symptom onset to consult in first healthcare facility was 48 hours (IQR: 44-72 hours). Eighteen patients (58.06%) were subsequently referred to a second facility after a median stay of 48 hours (IQR: 28-72 hours). At the secondary or tertiary referral center, diagnostic neuroimaging was performed after a median of 48 hours (IQR: 36–108 hours). Anticoagulation was initiated within a median of 2 hours (IQR: 2–2.75 hours) following the diagnosis of CSVT. Although all patients survived, 32% had neurologic sequelae at discharge which persisted at the 2-year follow-up. Complete vessel recanalization on follow-up neuroimaging was achieved in all anticoagulated patients, compared with 66.7% of those who were not anticoagulated. However, statistical analysis showed no significant association between anticoagulation therapy and either clinical outcome or vessel recanalization. Conclusion: Neonatal CSVT associated with AKI can lead to persistent neurologic deficits at 2 years. Timely diagnosis and management remain a significant challenge in resource-limited settings due to delays both before and during hospitalization. Although anticoagulation treatment was not associated with outcomes in our cohort, further research is needed to develop acute care guidelines, applicable across diverse clinical settings, particularly in resource limited situations.
Keywords: Pediatric Stroke, stroke management, Systems of care, pediatric acute stroke protocols, CSVT
Received: 25 Aug 2025; Accepted: 21 Nov 2025.
Copyright: © 2025 Parakh, Tan and Meena. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Manish Parakh, manparkh@hotmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.